Clinical Guidelines for Maternal Hematologic Disorders

Abstract

Hematologic disorders in pregnancy represent a significant challenge due to their impact on both maternal and fetal outcomes. This review synthesizes current clinical guidelines, recent research, and evidence-based recommendations for the diagnosis, management, and monitoring of common maternal hematologic disorders, including anemia, thrombocytopenia, thromboembolic disease, and hemoglobinopathies. The article emphasizes an integrated approach combining pathophysiological understanding with guideline-directed interventions, offering clinicians practical guidance for optimizing care in this vulnerable population.

Introduction

Maternal hematologic disorders encompass a wide spectrum of conditions ranging from benign to life-threatening, frequently complicating pregnancy and contributing to maternal and perinatal morbidity and mortality. The physiological changes of pregnancy can both mask and exacerbate hematologic abnormalities, necessitating a high index of suspicion, timely diagnosis, and evidence-based management. This review provides a comprehensive overview of clinical guidelines for maternal hematologic disorders, focusing on epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, management strategies, emerging therapies, and practical guideline recommendations for healthcare professionals.

Epidemiology / Disease Burden

Hematologic disorders are among the most common medical complications in pregnancy. Iron deficiency anemia affects up to 40% of pregnant women globally, with higher prevalence in low-resource settings. Thrombocytopenia occurs in 7–12% of pregnancies, while venous thromboembolism (VTE) remains the leading cause of maternal mortality in developed countries, with an incidence of 1–2 per 1,000 pregnancies. Hemoglobinopathies, such as sickle cell disease and thalassemia, are regionally prevalent and increasingly encountered due to global migration. These disorders are associated with increased risks of preterm birth, intrauterine growth restriction, and adverse maternal outcomes, highlighting the importance of early recognition and intervention.

Pathophysiology

Pregnancy induces profound hematologic adaptations, including increased plasma volume, hemodilution, and hypercoagulability. Anemia typically results from iron deficiency, folate or vitamin B12 deficiency, or hemoglobinopathies, while thrombocytopenia may be gestational, immune-mediated (ITP), or related to preeclampsia/HELLP syndrome. Hypercoagulability, driven by elevated procoagulant factors and decreased fibrinolysis, predisposes to thromboembolic events. Understanding these mechanisms is crucial for risk stratification and tailored management, as underlying pathophysiology influences both clinical course and response to therapy.

Risk Factors

Key risk factors for maternal hematologic disorders include advanced maternal age, multiparity, obesity, pre-existing hematologic conditions, nutritional deficiencies, chronic diseases (renal, autoimmune), family history, and ethnicity. Additional risk factors specific to VTE include immobility, cesarean delivery, inherited thrombophilia, and previous thrombotic events. Identifying modifiable and non-modifiable risk factors enables targeted screening and preventative strategies in clinical practice.

Clinical Features

Clinical manifestations vary by disorder and severity. Anemia may present with fatigue, pallor, tachycardia, and dyspnea, but often remains asymptomatic until severe. Thrombocytopenia is frequently discovered incidentally; however, severe thrombocytopenia can cause mucocutaneous bleeding or petechiae. VTE presents with unilateral leg swelling, pain, or respiratory symptoms in the case of pulmonary embolism. Hemoglobinopathies can manifest as vaso-occlusive crises, acute chest syndrome, or aplastic episodes. Awareness of these features is essential for timely diagnosis and management, particularly when symptoms overlap with normal pregnancy changes.

Diagnosis

Diagnosis relies on a combination of clinical assessment, laboratory evaluation, and imaging. Complete blood count is foundational, supplemented by peripheral smear, reticulocyte count, iron studies, vitamin B12/folate levels, and hemoglobin electrophoresis as indicated. Platelet count and coagulation profiles are critical for thrombocytopenia and coagulopathies. Doppler ultrasonography is first-line for suspected deep vein thrombosis, while ventilation-perfusion scanning or CT pulmonary angiography is used for pulmonary embolism. Rigorous diagnostic algorithms minimize unnecessary interventions while ensuring prompt recognition of serious pathology.

Treatment & Management

Management strategies are guided by etiology, severity, gestational age, and maternal-fetal risk assessment. Iron deficiency anemia should be treated with oral or intravenous iron depending on severity and tolerance. Folate and vitamin B12 deficiencies require appropriate supplementation. For hemoglobinopathies, supportive care, transfusions, and careful monitoring are essential, with hydroxyurea generally avoided in pregnancy. Thrombocytopenia management ranges from observation in mild gestational cases to corticosteroids or IVIG in ITP, and urgent delivery in severe preeclampsia/HELLP. VTE is managed with low molecular weight heparin, with anticoagulation continued for at least six weeks postpartum. Multidisciplinary care, including hematology and maternal-fetal medicine, is often required for complex cases.

Recent Advances / Emerging Therapies

Recent advances include the use of newer oral iron formulations with improved tolerability, individualized transfusion thresholds, and risk-adapted anticoagulation protocols. Non-vitamin K oral anticoagulants (NOACs) are under investigation but not yet standard in pregnancy due to limited safety data. Genetic screening for hemoglobinopathies and thrombophilias is increasingly accessible, enabling preconception counseling and early intervention. Advances in point-of-care testing and telemedicine facilitate rapid diagnosis and remote management, particularly in resource-limited settings.

Guideline Recommendations

Current guidelines from organizations such as ACOG, RCOG, and ISTH emphasize routine screening for anemia and thrombocytopenia, risk assessment for VTE, and individualized management based on disease severity and maternal-fetal risk. Universal iron supplementation is recommended in high-prevalence areas, with targeted therapy elsewhere. Thromboprophylaxis is advised for women with prior VTE, inherited thrombophilia, or multiple risk factors. Delivery planning should consider hematologic status, with close postpartum monitoring due to ongoing risk. Multidisciplinary care coordination and patient education are strongly advocated to optimize outcomes.

Conclusion

Maternal hematologic disorders require vigilant screening, accurate diagnosis, and guideline-based management to mitigate risks for both mother and fetus. Recent advances offer promise for improved outcomes, but individualized care and adherence to evolving guidelines remain paramount. Ongoing research, education, and multidisciplinary collaboration will continue to refine best practices and support optimal maternal and perinatal health.